Continued research is critical to potentially bring a targeted therapeutic option to patients with higher-risk myelodysplastic syndromes, to improve overall survival, manage symptoms, and preserve quality of life.
By Justin Watts, MD
Advertisement
Articles by By Justin Watts, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer
2
KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC
3
GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026
4
Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma
5